FDA
-
-
-
-
-
-
-
Pliant Therapeutics to Participate in Upcoming Investor Events
-
-
-
-
-
-
-
Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1
-
-
-
-
-
-
-
Pliant Therapeutics (PLRX) Appoints Minnie Kuo as Chief Development Officer
-
-
-
-
-
-
-
Pliant Therapeutics to Participate in Upcoming Investor Conferences
-
-
-
-
-
-
-
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multi
-
-
-
-
-
-
-
Pliant Therapeutics Announces Positive DSMB Safety Review and Initiation of Enrollment of Phase 2a Trial of Bexotegrast (PLN-74809) at 320 mg Dose in Primary Sclerosing Cholangitis
-
-
-
-
-
-
-
Pliant Therapeutics to Participate in Upcoming Investor Events
-
251,349 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All